Julia Schüler, PhD, studied veterinary medicine at the Freie Unversität Berlin (Germany) and at the Tierspital Zürich (Switzerland), where she received her DVM. She then joined the lab of Prof. Dr. Heiner Fiebig, founder of Oncotest GmbH, where she worked on orthotopic implantation of solid cancer PDX in immunocompromized mice.
After receiving her PhD from the University of Berlin, Dr. Schüler worked in the field of innate immunology at the Max-Planck Institute for Immunobiology, Freiburg, in the group of Dr. Marinus Lamers and Dr. Thomas Böhm, focusing on Toll-like receptor signaling. She later re-joined Oncotest, holding leadership positions in in vivo contract research as well as R&D.
CRISPR's Rogue Tendencies (Eureka)
The Human Parts of Mouse Models (Contract Pharma)
Knock-Out Punch in Breast Cancer Mouse Study (Eureka Blog)
Translating Science into Survival (Eureka Blog)